We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Centers for Medicare & Medicaid Services (CMS) has backed away from its controversial plan that would have removed protected status for antidepressants and immunosuppressants in formularies under Medicare Part D. Read More
The congressional drumbeat of opposition to Zogenix’s painkiller Zohydro ER continues, with two Democratic senators ratcheting up the rhetoric by calling for HHS to revoke the controversial drug’s approval. Read More
The partnership will bring together researchers to discover and develop new drugs for autoimmune diseases currently treated with small-molecule biologics. Read More
Drugmakers seeking marketing authorization in Australia will soon be able to make complete submissions in electronic format, allowing for cost savings and potentially swifter reviews. Read More
Generic drugmakers in the EU must create a program to assess the effectiveness of their risk minimization efforts for each marketed drug, EU regulators say. Read More
Beginning on June 16, whenever a drugmaker receives approval for a generic drug by an EU member state, it will have 15 calendar days to report the approval to the EMA’s new centralized electronic registry. Read More
The FDA is telling drugmakers not to file supplemental applications for minor postapproval manufacturing changes such as swapping excipient suppliers, moving a manufacturing process within a plant or removing coloring or flavoring ingredients from a drug. Read More
Baxter and Sagent Pharmaceuticals are the latest generic drugmakers to recall products with leaky containers, notifying healthcare providers that affected product may be contaminated with particulates. Read More
New GOP-proposed legislation aimed at curbing prescription drug abuse would require certain generic drugmakers to conduct background checks and perform drug testing for employees with access to controlled substances. Read More
FDA efforts to standardize capsule and tablet sizes for generic drugs are unnecessary and will strain relationships with suppliers, generic drugmakers say. Read More
The White House on March 4 proposed increasing funding for the FDA in fiscal 2015 by eight percent above fiscal 2014, a slight bump that includes a $6 million increase in GDUFA user fees. Read More